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DOI 10.1186/s12885-015-1128-xRESEARCH ARTICLE Open AccessCancers of unknown primary origin (CUP) are
characterized by chromosomal instability (CIN)
compared to metastasis of know origin
Jonas Vikeså1†, Anne Kirstine H Møller2†, Bogumil Kaczkowski3†, Rehannah Borup1†, Ole Winther2,5,
Ricardo Henao2,5, Anders Krogh2, Katharina Perell2, Flemming Jensen4, Gedske Daugaard2† and Finn C Nielsen1*†Abstract
Background: Cancers of unknown primary (CUPs) constitute ~5% of all cancers. The tumors have an aggressive
biological and clinical behavior. The aim of the present study has been to uncover whether CUPs exhibit distinct
molecular features compared to metastases of known origin.
Methods: Employing genome wide transcriptome analysis, Linear Discriminant Analysis (LDA) and Quadratic
Discriminant Analysis (QDA), we defined the putative origins of a large series of CUP and how closely related a
particular CUP was to corresponding metastases of known origin. LDA predictions were subsequently used to
define a universal CUP core set of differentially expressed genes, that by means of gene set enrichment analysis
was exploited to depict molecular pathways characterizing CUP.
Results: The analyses show that CUPs are distinct from metastases of known origin. CUPs exhibit inconsistent
expression of conventional cancer biomarkers and QDA derived outlier scores show that CUPs are more distantly
related to their primary tumor class than corresponding metastases of known origin. Gene set enrichment analysis
showed that CUPs display increased expression of genes involved in DNA damage repair and mRNA signatures of
chromosome instability (CIN), indicating that CUPs are chromosome unstable compared to metastases of known origin.
Conclusions: CIN may account for the uncommon clinical presentation, chemoresistance and poor outcome in
patients with CUP and warrant selective diagnostic strategies and treatment.
Keywords: Carcinoma of unknown primary, Chromosome instabilityBackground
Cancers of unknown primary origin (CUPs) are a het-
erogeneous group of cancers with variable clinical and
histological features for which no primary site of the
tumor can be identified despite an extensive diagnostic
work-up [1,2]. CUPs accounts for 3-5% of all cancer
diagnoses and about 85% of the patients have a very
poor prognosis [3]. Although a primary tumor cannot be
identified in about two-thirds of the cases, CUPs are
generally considered to represent metastases. The elusive
origin may partly be related to limitations in our* Correspondence: fcn@rh.dk
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unless otherwise stated.diagnostic procedures, but it may also indicate that
CUPs exhibit distinct biological features compared to
metastasis of known origin [4].
The prevalent model of metastasis is that cells from a
primary tumor invade the local environment and spread
to distant locations. Metastases may derive from more
or less differentiated cancer cells at different stages of
tumor growth and this may provide a substantial hetero-
geneity in the clinical presentation and nature of metas-
tases. Although micrometastases are enriched in cells
expressing stem cell markers, macrometastases share
many similarities to the primary tumor, so newly settled
cancer stem cells not only self-renew, but also foster dif-
ferentiated colonies of cancer cells [5]. Because metasta-
ses retain some of the characteristics of the primaryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Vikeså et al. BMC Cancer  (2015) 15:151 Page 2 of 14cancer, transcriptome signatures have been employed to
depict the origin of CUPs.
It is currently unknown if CUPs exhibit particular gen-
etic and phenotypic characteristics compared to metas-
tases of known origin. The challenge in addressing this
problem is obviously that CUPs per definition are of un-
known origin. To circumvent this problem, we generated
a molecular signature that could classify a wide number
of known primary tumor classes and their metastases
with high accuracy.
We used the expression signature to classify the CUPs
and included a Quadratic Discrimination Analysis (QDA)
to generate an outlier score depicting how closely related
a particular sample is to the different kinds of primary tu-
mors. Subsequently, we used the LDA predicted classifica-
tion to make a paired analysis comparing CUPs to their
equivalent metastasis of known origin (MOKO), to define
a CUP core set of differentially expressed genes that could
provide leads to the molecular pathology of CUPs.
We demonstrate that CUPs exhibit a number of dis-
tinct molecular features that distinguish them from con-
ventional metastasis. CUP gene expression signatures
are more distantly related to their predicted primary
tumor classes than signatures of metastases known ori-
gin, and they exhibit an inconsistent expression of
conventional cancer biomarkers. CUPs are enriched in
BRCA1, ATM and CHEK2 DNA damage and homolo-
gous recombination repair networks suggesting that
CUPs are chromosome unstable and this was corrobo-
rated by the demonstration of signatures of chromosome
instability (CIN) in CUPs. The results indicate that
CUPs may warrant selective diagnostic and therapeutic
strategies distinct from the current platinum based and
organ specific therapy.
Methods
Gene expression profiles for tumor classification
Expression profiles of more than 2400 tumor samples were
downloaded from the Gene Expression Omnibus (GEO)
(http://www.ncbi.nlm.nih.gov/geo/) (Testset: GSE2109,
GSE7307, GSE6004, GSE6764, GSE10135, GSE2328,
GSE13471, GSE7392 and GSE12606) (Validationset:
GSE2109, GSE3325, GSE5764, GSE5764, GSE5787,
GSE7307, GSE7476, GSE7553, GSE10245, GSE11151,
GSE14762, GSE15471, GSE17537, GSE19826, GSE19829,
GSE20565) or generated from samples collected and proc-
essed at our own facility at Rigshospitalet (ArrayExpress,
E-MTAB-3222). Finally thyroid samples were retrieved
from ArrayExpress data base (accession E-MEXP-2442).
The specific identifiers of the samples are depicted in
Additional file 1: Table S1. The numbers refer to the
GSM number in the GEO profile data base and the name
(e.g. breast) refers to the biopsy tissue site. The material
comprised 15 classes of carcinomas from thyroid, lung,stomach, colon/rectum, pancreas, bile duct/gallbladder,
liver, kidney, urinary tract, prostate, breast, ovary, endo-
metrium, cervix uteri, testis cancer and 1 group of malig-
nant melanomas and finally a group with pooled normal
tissue samples from various organs that was included in
order to allow detection of samples without sufficient
tumor tissue. The 16 tumor classes were selected to repre-
sent the most frequently identified primary tumor sites in
CUP patients at autopsy, and primary tumors that are dif-
ficult to distinguish by IHC tools alone due to the lack of
specific IHC markers (e.g. upper GI) and/or tumor dedif-
ferentiation. Each tumor class contained the most com-
mon histological subtypes. Sample IDs are indicated in the
enclosed Additional file 1: Table S1. The pathology de-
scriptions were reviewed in order to group the samples
into tumor classes and this ultimately resulted in a set of
1466 expression profiles from well-defined primary tu-
mors (1299) and normal tissue (167) (Additional file 1:
Table S1). The classifier was tested on an independent
validation set including 641 tumor samples (391 primary
tumors and 250 metastases) from all 16 tumor classes
(Additional file 1: Table S1).
CUP patients and samples
CUP patients were consecutively enrolled between
November 2004 and September 2010 for diagnostic work-
up and treatment. Newly diagnosed CUP patients were re-
ferred to the Department of Oncology (Rigshospitalet) for
further diagnostic work-up and treatment. All patients
had a biopsy-proven metastatic cancer and had undergone
diagnostic work-up at the referral hospitals. At the Depart-
ment of Oncology at Rigshospitalet further diagnostic
work-up was performed including revision of biopsies by
an experienced pathologist, new biopsies and further im-
aging procedures. A schematic representation of the CUP
patients and the inclusion of samples are shown in
Additional file 2: Figure S1. Patients were included when
the diagnostic work-up, as recommended by the European
Society of Medical Oncology (ESMO) [6], failed to identify
a primary site of origin. At least two ultra-sonography-
guided biopsies – one for histopathological work-up and
one for gene expression profiling – were obtained from all
patients. Patients, in whom a putative a primary tumor site
eventually was identified in the diagnostic work-up period,
were treated according to national guidelines whereas
most CUP patients were offered platin/taxane-based regi-
mens as first-line treatment. The study was approved by
the Danish RegionH ethical committee and patients had
given their written informed consent and have consented
for publication and disclosure of clinical data.
Microarray analysis and expression values
Total RNA was isolated, labeled and hybridized as de-
scribed [7]. Cell files were pre-processed using the Robust
Vikeså et al. BMC Cancer  (2015) 15:151 Page 3 of 14multi-chip average (RMA) method [8] and evaluated for
quality parameters with the Simpleaffy functionality of
the R/Bioconductor packages. The data sets were fil-
tered to exclude probe sets with Interquartile Range
(IQR) below 0.8.
Tumor classification and outlier analysis
Linear discriminant analysis (LDA) was used for classifi-
cation as implemented in the R language. Briefly, in
LDA the predictive probability of class c given input x is
computed using Bayes’ theorem p(c|x) = p(x|c) p(c)/p(x),
where p(x|c) is a normal density specific for the class,
p(c) the a priori probability of class c and p(x) = sum_c
p(x|c) p(c) the density of the input according to the
model. Maximum likelihood is used to fit p(x|c) and
p(c), c = 1,…,17 on the training data. In order to con-
struct a gene signature for our classifier we used leave‐
one‐out cross validation (LOOCV), where for each
split, feature selection by F-test were applied prior to
LDA. A grid search over p-value cut-offs yielded the
cut-off with the optimal LOOCV accuracy. The signa-
ture was eventually selected by an F-test using the opti-
mal p‐value cut‐off on the full set of 1466 training
samples, resulting in 428 probes (311 unique genes).
The performance of this first (428 probe) classifier was
then assessed using the independent 641 sample valid-
ation set. We merged the original training and valid-
ation set and used the found p-value cut-off (giving 641
probes) to generate a second classifier optimized for
CUP prediction. The performance of this classifier was
assessed using LOOCV. Finally, the LDA classifier was
made sex-specific by setting the prior probabilities to
zero for sex specific cancers (ovary, cervical and pros-
tate) not occurring and in the sex in question renor-
malizing the remaining prior probabilities accordingly.
A low model density p(x) implied that the input x was
not similar to those in the training data. We therefore
defined an outlier score OS = –log p(x) and calculated
the OS for each sample in the LOOCV loop. We used
QDA (individual covariance of normals) rather than
LDA (shared covariance of normals) in this step.
Gene set enrichment analysis
A CUP core list of transcripts was defined by a paired ana-
lysis between CUP LDA predictions and corresponding
metastasis of known origin. The pairing was done by mak-
ing a linear model of the data by eliminating the difference
between the groups as implemented in the Qlucore Omics
Explorer™ software. Analysis of the CUP core lists (up and
down) was performed using the Broad Institutes MSig
“Compute overlaps for selected genes” function available
on the homepage http://www.broadinstitute.org/gsea/
msigdb). Gene symbols in the CUP core lists were ana-
lyzed for enrichments of Gene Onthology (GO) genesets(C5). CUP core lists were also analyzed for enrichments of
gene sets in the cu rated gene set database (C2). The C2
gene set collection is gathered from various online path-
way databases, publications from PubMed and knowledge
of domains experts (see homepage). A filter setting was
added to both analyses to show only gene sets with FDR
q-value below 0.01. GSEA on predefined gene sets were
performed using the Broad Institute GSEA v2 software.
The expression data matrix was preprocessed in the
Qlucore Omics Explorer™ software and expression values
were normalized within LDA predictions. The data set
was analyzed employing 1000 permutations with all the
default standard settings of the GSEA v2 software. Hier-
archical cluster analysis was performed and visualized
using the Qlucore Omics Explorer™ software. All hier-
archical clusters are build using average linkage and
heat map was generated based on mean m = 0, variance
1 normalization.
Results
CUP patients and tumor classification
Sixty eight consecutive CUP patients were enrolled in the
study, but since eleven samples did not meet the quality
criteria the number of CUP samples ended at 57. The
histological features of the 57 CUP that underwent ex-
pression profiling are summarized in Table 1. During the
diagnostic work-up, a possible primary tumor site was
eventually identified in 28 of the 57 patients (Additional
file 2: Figure S1 and Table 1). Among these 18 samples
were in accordance with diagnostic work-up or the
Standard of Reference.
To examine if CUP exhibit particular genetic and
phenotypic characteristics compared to metastases of
known origin, that could warrant particular diagnostic
procedures and treatment, we first generated a
transcriptome-based signature that could classify 16
common tumor classes and predict the origins of CUP
and metastases of known origin with high accuracy
(Detailed in Additional file 1: Table S1). To allow detec-
tion of samples without sufficient tumor tissue, a group
of normal tissues was also included. Since all CUP
data were generated at our facility, we moreover ex-
amined a series of primary cancers and metastases
from Rigshospitalet to exclude possible site- and batch-
specific effects. The cross-validation accuracy during train-
ing of a 428 probe sets classifier was 92.2% (Additional
file 3: Table S2) and the overall accuracy in the validation
set was 90% and 83% for primary tumors and known me-
tastases, respectively (Additional file 3: Table S2). The dis-
tribution of variables among the 16 tumor categories is
depicted in the heat map (Figure 1). Since we suspected
that the low accuracy in some of the classes, e.g. cholan-
giocarcinoma, was associated with the small number of
samples in the training set, and because CUPs were
Table 1 Prediction results in CUP patients
ID Sex Biopsy site Histology Path Diag. Stand of Ref LDA Pred Outlier score
14. F LN neck PDC Lung Lung (CD) Lung 975
17. F LN neck Adenoc. Lower GI Colon (RD) Colon 746
22. M LN neck Adenoc. CUP Stomach (RD) Normal 934
23. M LN retro PDC CUP Kidney (RD) Kidney 1085
28. F Peritoneum PDA Ovary Ovary (RD) Ovary 810
31. F LN neck PDA CUP Lung (CD) Stomach 985
34 M Skin PDA Lung Lung (RD) Lung 898
39. M Liver Adenoc. CUP Pancreas (CD) Pancreas 1097
40. F Liver Adenoc. Colon Colon (RD) Colon 729
44. F Kidney Carc. CUP Bladder (RD) Bladder 1286
49. M LN neck PDA Kidney Kidney (RD) Kidney 1223
51. F LN pelvis SCC CUP-SCC Cervical (RD) Cervix 828
52. M Liver PDA CUP CCC (RD) CCC 923
53. M Liver Adenoc. Lung Lung (RD) Lung 1047
57. M Liver Adenoc. CCC CCC (RD) HCC 965
66. F Liver PDA CUP CCC (RD) Cervix 1100
70. M Peritoneum Adenoc. Stomach Stomach (CD) Colon 842
74. M Leg Carc. Adnex tumor Adnex tumor (RD) Normal 1010
76. M Liver Adenoc. Lower GI Small intestine (RD) Colon 912
77. M LN axilla PDC CUP Lung (CD) Breast 978
86. F LN axilla Adenoc. CUP Lung (RD) Stomach 1108
88. F Peritoneum Adenoc. Ovary Ovary (RD) Cervix 1033
89. F Liver PDA CCC CCC (RD) CCC 916
90. F Peritoneum Adenoc Ovary Ovary (RD) Ovary 781
92. M Liver Malignant tumor Angiosarcoma Angiosarcoma (RD) Normal 1097
95. M Peritoneum PDC DSRCT DSRCT (RD) Breast 1098
71 + 72 M Bone + Kidney PDC Kidney Kidney (RD) Kidney 1096
1277
75 + 87 F/43 Liver PDA CCC CCC (RD) CCC 925
1030
ID Sex Biopsy site Histology Path Diag. Stand of Ref LDA Pred Outlier score
11. F LN neck PDA CUP CUP (SD) Ovary 756
13. F Peritoneum PDA CUP CUP (NSD) Pancreas 1193
21. M LN neck PDC CUP CUP (NSD) Breast 1108
26. F Skin PDA CUP CUP (NSD) Breast 971
32. M LN neck PDSCC CUP-SCC CUP (NSD) Normal 926
33. M Skin PDA CUP CUP (NSD) Colon 1098
41. M Liver PDA Pancreas CUP (NSD) Stomach 1040
42. M Liver Adenoc. CUP CUP (NSD) Pancreas 994
43. F LN retro PDA CUP CUP (NSD) Stomach 797
45. M Liver PDC CUP CUP (NSD) Colon 1245
46. F Liver Adenoc. CUP CUP (NSD) Normal 1027
47. F Liver Adenoc. CUP CUP (SD) CCC 932
48. F LN neck PDC CUP CUP (NSD) Ovary 1032
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Table 1 Prediction results in CUP patients (Continued)
54. F Liver Adenoc. CUP CUP (NSD) Normal 1068
55 F Liver Adenoc. CUP CUP (NSD) Normal 962
58. F Liver PDC CUP CUP (SD) CCC 995
61. M Liver Carc. HCC CUP (NSD) CCC 1102
64. F LN inguien PDA CUP CUP (SD) Lung 1168
65. M LN neck PDSCC CUP-SCC CUP (NSD) Breast 929
73. M LN retro PDC CUP CUP (NSD) Normal 1020
78. F Lung Adenoc. Lower GI CUP (NSD) Lung 1062
80. F Liver Adenoc. CUP CUP (SD) CCC 1111
81. F Liver PDA CUP CUP (NSD) Breast 1212
82. F Bone Adenoc. CUP CUP (NSD) CCC 1209
83. F Liver PDA CUP CUP (SD) CCC 1061
91. F LN axilla Adenoc. CUP CUP (SD) Lung 939
93. M Bone PDSCC CUP-SCC CUP (NSD) Breast 940
94. F Liver PDA CUP CUP (NSD) Normal 984
50. + 68 M Adr gl PDC CUP CUP (NSD) Stomach 978
Pancreas 1079
A validation of the LDA predicted diagnoses was performed by comparing with a Standard of Reference (SR). SR was established by an experienced pathologist
and two experienced oncologists. In addition to the 23 patients where a primary tumor site was identified (Reference Diagnosis (RD)) within the study period, the
Standard of Reference reached a Consensus Diagnosis (CD) in 5 patients based on patient demographics, metastatic pattern, results of clinical and laboratory
tests, imaging data and pathologic evaluations (Samples labeled in red). In the 29 remaining CUP labeled in blue, the results from gene expression profiling were
compared with clinicopathological features and the predictions were categorized as Supportive (SD) or Non-Supportive (NSD). LN: lymph node; n: neck LN; m:
mediastinal LN; a: axilla LN; r: retroperitoneal LN; p: pelvis LN; adr gl: adrenal gland; Adenoc: adenocarcinoma, PDA: poorly differentiated adenocarcinoma; Carc:
carcinoma; PDC: poorly differentiated carcinoma; SCC: squamous cell carcinoma; PDSCC: poorly differentiated SCC; CCC: cholangiocarcinoma; HCC: hepatocelluar
carcinoma; DSRCT: desmoplastic small round cell tumor.Path Diag: pathological diagnosis; Stand of ref: Standard of reference; LDA pred: Linear discriminant
analysis prediction; RD: Reference Diagnosis; CD: Consensus Diagnosis, SD: Supportive Diagnosis; NSD: Non-Supportive Diagnosis.
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we subsequently combined the training and validation sets
and generated a second classifier, consisting of 641 probe
sets (641 classifier). Furthermore a gender correction by
renormalizing the prior class probabilities in the test situ-
ation was implemented because we noted that tumors
from males incorrectly were classified as ovary, cervical
and endometrial cancer. The accuracy in primary tumors,
known metastases and normal samples of the 641 classifier
was 92%, 87% and 89%, respectively (Additional file 3:
Table S2) and this classifier was subsequently used for the
prediction of CUP. The principal component analysis is
shown in Figure 1B and the ten most selective transcripts
and their gene ontology for each tumor class are listed in
Additional file 4: Figure S2.
To provide a systematic overview of the expression of
conventional tumor markers in the CUP samples, we
also compiled a list of 45 common histopathological bio-
markers and depicted their expression in a two-way hier-
archal cluster (Figure 2). Whereas, about 85% of the
primary cancers exhibited a characteristic expression of
their individual histomarkers, only 10 of the 28 (35%)
CUP - where a putative primary site was identified and 3
of the 29 (10%) CUP - where the primary site remained
unknown - expressed one or more biomarkers atsignificant levels. The strongest overlap between histo-
pathological markers and the LDA based CUP classifica-
tions was observed for CUP predicited as ovary and
colorectal cancers, where 4 and 3 samples expressed
WT1 or CEA/CEACAM5, respectively. Moreover, 6 sam-
ples were positive for TP63 and 2 samples were positive
for surfactant proteins. Finally, one sample was positive
for PAX2 in agreement with the LDA prediction as renal
carcinoma. Compared to the primary cancers there was
a limited concordance between markers within the same
tumor category. Only two of the WT1 positive cancers
were positive for CA125/MUC16, and only 3 of the
TP63 positive samples expressed CK17 and CK5, charac-
teristic of squamous carcinoma. If the histological
markers were combined and used in an LDA based fash-
ion, the concordance with the 641 signature LDA pre-
dictions or Standard of Reference was about 66%
indicating that systematic application of the patomarkers
may at least to some extent compensate for the modest
predictive power of individual markers.
QDA based outlier analysis
To determine the similarity between primary cancers,
metastases of known origin and CUPs, we employed
Quadratic Discriminant Analysis (QDA) to determine
Figure 1 Hierachial cluster and principal component analysis of tumor classes. A. Two-way hierachial cluster of 16 tumor classes by the 641
transcript signature. The tumor classes are shown at the top of the cluster and the transcripts are clustered at the left side. B. Principal component
analysis (PCA) of primary tumors and known metastases based on the signature. The tumor classes are colored and indicated in association with
the corresponding tumor samples.
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of the predefined tumor classes. Outlier scores were cal-
culated in LOOCV fashion for one sample at a time
using all remaining samples i.e. primary tumors and me-
tastases to represent the classes. The outlier scores of
the samples from normal tissues are not comparable to
the primary tumors and metastases because of the het-
erogeneity among the many different tissues in the class.
Based on the results from primary tumors and metasta-
ses we plotted the predictive error rates versus the outlier
scores and demonstrated a clear relationship between er-
rors and outlier scores (Figure 3). Samples with outlier
scores below 800 exhibited less than 10% risk of being er-
roneous, whereas, outlier scores above 1000 had more
than 25% risk of being incorrect. However, even in the
high end of outlier scores with only 75% accuracy, predic-
tion is far from random, since we are working with 16 dif-
ferent classes. As shown in the box plot (Figure 3), CUP
samples had significantly higher outlier values than pri-
mary tumors and metastases. To ensure that the differ-
ence was not related to our platform, we compared our
own samples of known metastases and primary tumorsand observed the same difference. CUPs, moreover, con-
sisted of biopsies that may contain more normal tissue
than samples obtained during surgery. We therefore plot-
ted the percentage of normal tissue as estimated from the
relative expression of markers of lymphoid, liver, and
muscle tissue versus the outlier scores, but observed no
correlation between the amount of normal tissue in the bi-
opsies and the outlier scores (Additional file 5: Figure S3).
A number of samples that expressed conventional histo-
pathological biomarkers exhibited low scores, but if we
compared CUPs where a primary cancer was identified
during the clinical processing with CUPs where no
primary site could be identified, there was no difference
between the outlier scores (mean 991 vs mean 1031, P =
0.24). Taken together, the results demonstrate that CUPs
are more distantly related to the predefined tumor classes,
than known metastases.
mRNA Expression and Gene Set Enrichment in CUP
To identify differentially expressed transcripts, we per-
formed a class comparison between CUP and metastases
of known origin. The analysis was performed as a paired
Figure 2 Patomarkers in primary tumors and CUP. Probeset Ids for 45 common histopatological markers were collected and used to
generate a two-way hierarchal cluster with a selection of primary tumors (Panel A) or CUP (Panel B). The variance of the individual markers is
shown to the left and the scale is indicated at the top of the clusters. Gene symbols are shown to the right and the different tumor classes are
shown below ((Panel A), primary tumors). For the CUP samples (Panel B), groups of markers corresponding to different tumor classes are
indicated by the boxes around the gene symbols at the right side of the cluster. The number below the cluster indicated the number of the CUP
sample corresponding to the annotation in Table 1.
Figure 3 QDA derived outlier scores in CUP. A) To determine the relationship between prediction error and outlier scores the primary cancers
and metastases were divided into ten bins according to the outlier scores and the error rate was calculated for each bin. Each point represents
the error rate plotted versus the median outlier score of the bin. The vertical lines show the span of outlier scores within the bins. The plot shows
that higher outlier score translates into higher error rate. We modeled the relationship between outlier scores and prediction error by fitting
polynomial function to the data points (the orange line), and the function allows us to estimate the expected error rate for new samples of
unknown origin, once their outlier scores have been determined. B) Samples from CUP patients tend to have higher outlier scores than other
cancer patients. The box plot summarizes the distributions of outlier scores within metastases (MET), primary (PRIM) and CUP tumors. There is a
clear tendency for CUP samples to have higher outlier score than metastases and primary cancers. The median outlier score of CUP samples of >1000
suggests the origin prediction error above 30%. On the other hand, most primary cancers and metastases have outlier scores below 800, hence the
estimated prediction error from 2-10% (see panel A). Since data for CUP and some primary tumors and metastases were generated at Rigshospitalet,
the non-CUP samples from Rigshospitalet are presented as separate group (RH_MET and RH-PRIM), this is to show that the shift in outlier scores was
not caused by technical bias. Additionally, the normal, non-cancerous tissue group (NORMAL) is included, and shows the whole range of outlier scores.
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differences between tumor classes. Metastases from uter-
ine, testis, prostate, melanoma and thyroid cancers were
excluded from the analysis because no CUPs had been al-
located to these groups. CUPs predicted as normal tissue
were also excluded. Moreover, cholangiocarcinomas were
omitted from the calculations because they were not rep-
resented in the LDA predicted metastases group. In total
41 CUP and 186 metastases comprising 10 different can-
cer groups were included in the analysis. To define the
most up- and down-regulated CUP transcripts, a cut-off
of p < 10−8 corresponding to a false discovery rate of q <
1.9*10−7 was employed. This resulted in 1550 down- and
1390 up-regulated probe sets corresponding to 1117 and
934 unique annotated genes, respectively. These two lists
comprised our CUP core set of differentially expressed
transcripts. The 40 most significantly down- or up-
regulated mRNAs are shown in Additional file 6: Table S4.
The lists of genes was subsequently subjected to a Gene
Set Enrichment Analysis (GSEA) using the Broad Insti-
tute’s GSEA database (http://www.broadinstitute.org/gsea/
msigdb). Initially, we searched for enriched gene ontology
terms, and this revealed that up-regulated transcripts were
associated with GO-terms (q < 0.01): DNA_INTEGRITY_
CHECKPOINT,DNA_DAMAGE_CHECKPOINT,DNA_
REPLICATION_INITIATION,DNA_PACKAGING,
NEGATIVE_REGULATION_OF_DNA_METABOLIC_
PROCESS,CELL_CYCLE_CHECKPOINT;NEGATIVE_
REGULATION_OF_DNA_REPLICATION,CHROMATIN_
REMODELING,DNA_DAMAGE_RESPONSESIGNAL_
TRANSDUCTION. There were no particular enrich-
ments among the down-regulated mRNAs.
To depict CUP enriched molecular pathways, we fur-
ther examined if the CUP core set exhibited overlaps
with the Molecular Signature Database (MSigDB) cu-
rated gene sets. Overlaps between the CUP core set (p <
10−8) were computed by submission of up- and down-
regulated probe sets separately (Table 2). Gene sets con-
sisting of transcripts that were positively correlated to
BRCA1, ATM and CHECK2 expression were highly
enriched in the up-regulated CUP core set. The down-
regulated CUP mRNAs showed fewer significant over-
laps but SHEN_SMARCA2_TARGETS_DN gene set,
which depict transcripts that are negatively correlated
with SMARCA2 expression in prostate cancer was
clearly overlapping with the CUP set.
To examine the BRCA1 and SMARCA2 pathway net-
works defined by the SHEN_SMARCA2_TARGET_DN,
SHEN_SMARCA2_TARGET_UP and PUJANA_BRCA1_
PCC_NETWORK in greater detail, we generated two
way clusters using the complete gene sets on our CUP
core set (Figure 4). The clusters were based on a paired
analysis with respect to their LDA predictions and with
the same inclusion criteria, as described above. TheSHEN_SMARCA2_TARGET_DN; SHEN_SMARCA2_
TARGET_UP and PUJANA_BRCA1_PCC_NETWORK
gene symbols were translated into probe sets and to ex-
clude non-functional redundant probe sets, only the
probe sets with the 50% highest variance were included.
We moreover applied a p-value cut-off of 0.001 to filter
probe sets that differed among the two groups (Figure 4).
The PUJANA_BRCA1_PCC_NETWORK set of genes
consists of 1671 gene symbols that translated into 3897
probe sets. Following filtering 705 probe sets correspond-
ing to 519 up-regulated and 66 down-regulated genes
were clustered (Figure 4). From the cluster it is apparent
that the BRCA1 profile is strongly enriched in CUP com-
pared to the corresponding metastases. A schematic rep-
resentation of the BRCA1 and non-homologous repair
networks showing the enriched factors is depicted in
Additional file 7: Figure S4. Following the same procedure,
we subsequently looked at the SMARCA2 networking
(Figure 4). The SHEN sets consist of 360 SMARCA2
negatively- and 430 SMARCA2 positively- correlated
genes that translated into 772 and 1211 probe sets respect-
ively. In the SMARC2A negatively correlated group, we
observed 20 genes that were up-regulated and 95 that
were down-regulated in CUP compared to metastases,
and amongst the SMARCA2 positive correlated genes we
saw 161 up-regulated genes and 19 down regulated after
filtering (top 50% variance probes and p < 0.001). Taken
together, the GSEA shows that CUPs are characterized by
enrichment of the double strand break DNA repair system
and the SMARCA2/BRM chromatin dependent remodel-
ing system.
Chromosome instability in CUP
Since the observed enrichment of genes involved in DNA
double-strand break repair (Additional file 7: Figure S4)
indicated that CUPs were more chromosome unstable
than known metastasis and primary cancers, we examined
the status of signatures involved in DNA repair and gen-
ome instability. Signatures of chromosomal instability
(CIN), DNA double-strand break repair, nucleotide exci-
sion repair (NER), base excision repair (BER) and mis-
match repair (MMR) were included to obtain a complete
overview of DNA- repair and stability in CUP (Figures 5
and 6). The predefined gene sets were examined with the
Broad Institute GSEA v2 software. The expression data
matrix was preprocessed in Qlucore Omics Explorer™ and
expression values were normalized within LDA predic-
tions - so the expression values became expressed as a
relative value compared to the mean expression of a gene
within its group. The data set was analyzed against the 10
selected gene sets (Figure 5) employing 1000 permutations
with standard GSEA settings. The most significant scores
were observed for the signature of double strand break re-
pair and for signatures of unstable sarcoma [9] and CIN
Table 2 Enriched or depleted gene sets in CUPs compared to metastases of known origin
Up-regulated in CUP
Gene Set name Transcripts Overlap k/K p value
PUJANA_BRCA1_PCC_NERWORK
Genes constituting the BRCA1-PCC network of transcripts whose expression positively correlated
(Pearson correlation coefficient, PCC > = 0.4) with that of BRCA1
1671 159 0.0952 0.00E + 00
KINSEY_TARGETS_OF_EWSR1_FLII_UP
Genes up-regulated in TC71 and EWS502 cells (Ewing’s sarcoma) upon knockdown of theEWSR1-FLII fusion 1281 133 0.1038 0.00E + 00
PUJANA_ATM_PCC_NETWORK
Genes constituting the ATM-PCC network of transcripts whose expression positively correlated
(Pearson correlation coefficient, PCC > = 0.4) with that of ATM
1461 152 0.104 0.00E + 00
PUJANA_CHEK2_PCC_NETWORK
Genes constituting the CHEK2-PCC network of transcripts whose expression positively
correlates (Pearson correlation coefficient, PCC > 0.4) with that of CHEK2
782 89 0.1138 0.00E + 00
DODD_NASOPHARYNGEAL_CARCINOMA_DN
Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue. 1375 157 0.1142 0.00E+00
RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP
Genes up-regulated in anaplastic thyroid carcinoma (ATC) compared to normal tissue. 721 93 0.129 0.00+00
MILI_PSEUDOPODIA_HAPTOTAXIS_UP
Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory
stimulus by fibronectin, FN1
552 74 0.1341 0.00E+00
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP
Genes up-regulated in poorly diffrentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue. 640 94 0.1469 0.00E+00
DECOSTA_UV_RESPONSE_VIA_ERCC3_DN
Genes down-regulated transcripts in fibrolasts expressing ethier XP/CS or TDD mutant forms of ERCC3
[Gene ID=2071], after UVC irradiation
855 126 0.1474 0.00E+00
DECOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN
Common down -regulated transcripts in fibroblasts expressing either XP/CS orTDD mutant forms of
ERCC3 [Gene ID=2071], after UVC irradiation
420 64 0.1524 0.00E+00
OSMAN_BLADDER_CANCER_UP
Common down-regulated in blood samples from bladder cancer patients 402 57 0.1418 5.55E-16
SENUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP
Genes up-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [Gene ID=9260],
a latent gene of Epstein Barr virus (EBV)
399 56 0.1404 155E-15
SENUPTA_NASOPHARYNGEAL_CARCINOMA_UP
Genes up-regulated in nsopharyngeal carcinoma relative to the normal tissue. 286 46 0.1608 3.33E+15
PUJANA_XPRSS_INT_NETWORK
Genes constituting the XPRSS-Int network: intersection of genes whose expression correlates with BRCA1,
BRCA2, ATM, and CHEK2 [Gene ID=672, 675, 472, 11200] in a compendium of normal tissues.
167 34 0.2036 1.21E-14
Down-regulated in CUP
Gene Set Name Transcripts Overlap k/K p value
SHEN_SMARCA2_TARGETS_DN
Genes whose expression negatively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer
samples
360 73 032028 0.00E+00
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN
Genes doen-regulated in non-metastic breast cancer tumors having type 1 amplifications in the 20q13
region; involves ZNF217 [Gene ID=7764] locus only.
336 49 0.1458 7.71E-11
Gene set enrichments among up or down regulated mRNAs in the CUP core set were examined in the molecular signatures database (MSig) among the C2
curated gene sets comprising profiles from chemical and genetic perturbations, canonical pathways, BIOCARTA, KEGG and the reactome collections. The
uncorrected p values are indicated. In all cases the false positive discovery rate was set to q < 0.01.
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Figure 4 Two way hierachial clusters of BRCA1 and SMARCA2 networks in metastases and CUP. (A) The PUJANA_BRCA1_PCC_NETWORK
was downloaded from the MSig database (http://www.broadinstitute.org/gsea/msigdb) and used to generate a paired two way hierarchical
cluster with known metastases and CUPs. Gene symbols were translated into probe sets and because of the probe set redundancy the data were
filtered by a p < 0.001 before clustering. Following filtering 1297 probe sets were included in the clustering. Known metastases are indicated in
green and CUP samples are labeled with pink above the cluster. The scale is shown at the right side of the cluster. (B) Two-way cluster of the
SHEN_SMARCA2_ TARGETS up- and (C) downregulated transcripts. The sets consists of 360 down- and 430 up-regulated genes that translated
into 772 and 1211 probe sets, respectively. The known metastases are indicated in pink and CUP samples are labeled with green below the
cluster. The scale is shown at the right side of the cluster.
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but not to a significant level (p = 0.123). The remaining
nucleotide excision and mismatch repair signatures were
not enriched in CUP and we infer that CUPs primarily
distinguishes themselves from metastasis of known origin
by signatures of chromosome instability. The signature of
chromosome unstable sarcoma was finally employed to
generate an instability score providing an index of thechromosomal instability for comparison of normal tissue,
primary cancers and metastasis and CUP (Figure 6). The
instability score was calculated as the mean of the expres-
sion values from the included probe sets of the signature
following variance filtering (206 probe sets). As shown in
Figure 6 panel B CUP exhibited a significantly higher score
than paired metastasis of known origin. Metastases were
significantly more chromosomal unstable than primary
Figure 5 Signatures of genomic instability in CUPs. Messenger RNA signatures of chromosomal instability (CIN), DNA double-strand break
repair, nucleotide excision repair (NER), base excision repair (BER) and mismatch repair (MMR) in CUPs and MOKO were examined with the Broad
Institute GSEA v 2 software. The names of the individual signatures, the number of transcripts and the normalized enrichment scores (NES) are
indicated. The right panel depicts the transcript ranking on a colometric scale. With the exception of the CIN signature obtained from [10] all
gene lists were retrieved from http://www.broadinstitute.org/gsea/msigdb.
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instability scores. We moreover examined the correlation
between outlier scores and instability scores, because
chromosome instability is envisioned to promote evolution
and phenotypic variations. In a linear correlation analysis
including primary cancers, metastasis and CUPs the out-
lier scores were positively correlated with the chromo-
somal instability score (p < 7.24E-33; q < 2.16E-30), so we
infer that chromosomal instability is likely to be implicated
in the phenotypic traits of CUPs.
Discussion
To examine the biological differences between metasta-
sis of known origin and CUPs, we first developed a ro-
bust LDA classifier that could define the most likely
origin of a particular CUP on a molecular basis. In line
with a number of previous molecular prediction studies
[11-25] CUPs were predicted to mainly emanate from
bile duct/cholangiocarcinoma, breast, lung and colorec-
tal cancers (Additional file 8: Table S3). Quadratic discri-
mant analysis (QDA) was subsequently used to calculate
the distance of primary tumors, metastases and our CUP
samples to the nearest tumor class. In agreement with
the acquisition or loss of phenotypic traits compared to
their origin, CUPs were more distantly related to the
predefined tumor classes than known metastases.
The explanation for the disparity between CUPs and
known metastases could obviously be that CUPs were
derived from types or subclasses of cancers not repre-
sented among our 16 classes, but a number of argu-
ments speak against this. Firstly, autopsy and previous
molecular classification studies support that the vastmajority of CUPs are likely to originate from the in-
cluded tumor classes [26]. Secondly, the genetic signa-
ture was selected by means of an F-test considering the
entire class, so class specific transcripts are supposed to
be present even in putative subclasses. Thirdly, high out-
lier scores were also observed among classes such as
colorectal cancers that are not known to contain sub-
classes. Finally, if a number of CUPs represented rare
cancers, the majority of the CUP scores should have
overlapped with metastases of known origin. So, taken
together, we infer that the observed difference in outlier
scores is likely to reflect that CUPs exhibit distinct mo-
lecular features.
Attempts to elucidate the molecular biology of CUPs
have been hampered by the heterogeneity of the cancers
and their elusive origins. Previous studies have indicated
that activation of MAPK, cMET and pAKT axes were
associated with progression and outcome in CUPs,
whereas p21 expression conferred a favorable prognosis
[27-29]. Based on the LDA predictions it became, how-
ever, possible to define CUP enriched transcripts and
molecular pathways in a paired analysis with metastasis
of known origin. At the single transcript level one of
the most consistently down-regulated factors was early
growth response 1 (EGR1), which is involved in cell
growth and differentiation. Suppressed EGR1 levels
have previously been reported in breast carcinoma [30],
glioblastoma [31] and lung [32] cancer, where it was
predictive of poor outcome.
The search for gene set enrichments moreover showed
that CUPs were enriched in transcripts encoding BRCA1,
ATM and CHEK2 DNA damage and homologous
Figure 6 Chromosomal instability and outlier scores in CUP. Panel A. Two-way hierachial cluster of the Ferreira_Ewing_Sarcoma_Unstable
signature in MOKO and CUPs. MOKO and CUPs are indicated by green and pink labels, respectively. Panel B. Instability scores in Normal tissues,
Primary tumors, MOKO and CUPs. The signature of chromosome unstable sarcoma was employed to generate an instability score calculated as
the mean of the expression values from the included probe sets of the signature following variance filtering (206 probe sets). Panel C. Linear
correlation between outlier scores and instability scores. Primary tumors, metastasis of known origin and CUP are indicated as black, red or green
dots, respectively. The lower panel shows the value of the instability scores depicted in a green to red color scale. The p-value of the linear
correlation between outlier and instability scores is indicated.
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chromosome unstable. This was corroborated by the dir-
ect demonstration of mRNA signatures of chromosome
instability (CIN) in CUPs. CIN is strongly associated with
poor outcome and drug resistance [10], and CIN positive
tumors reconcile many of the characteristics of CUP (for
review [33]). Previous analyses of the cytogenetic profile of
CUPs have also shown that chromosomal changes are fre-
quent and widespread in CUP and that CUPs exhibiting
large numbers of chromosomal aberrations have a poor
outcome [34]. CUPs are moreover frequently resistant toplatinum salts (for review [35] in agreement with the pres-
ence of CIN and concurrent up-regulation of the homolo-
gous recombination repair [36].
The molecular basis of CIN in sporadic cancers is in-
completely understood but oncogene induced collapse of
DNA replication forks, leading to DNA double strand
breaks and genomic instability is considered an appealing
model [37]. CIN is a major driving force for tumorigenesis
because it promotes accumulation of transforming geno-
types and increases the acquisition of independent pheno-
typic traits, that may translate into atypical presentations
Vikeså et al. BMC Cancer  (2015) 15:151 Page 13 of 14[38]. In agreement with this we observed a clear correl-
ation between the CIN score and the outlier scores that
portrays the similarity of the cancers to known groups.
Systemic cancer progression has been proposed to occur
via two models. The prevailing model states that cancer
progression occurs within the primary tumor before meta-
static dissemination of fully malignant cells, whereas the
second brings forward that cells disseminate from the pri-
mary tumor at an early stage and pursues a parallel and
independent progression of metastases (reviewed in [39]).
The two models provide a rationale for the observed dif-
ference between metastases of known origin and CUPs,
because the parallel progression predicts greater disparity
between metastatic founders and primary tumor cells than
does linear progression. By inference, CIN is likely to fa-
cilitate parallel progression by the early accumulation of
distinct genetic and epigenetic alterations in the primary
tumor and metastases. Moreover, tumor cells are pre-
dicted to settle at unconventional sites due to their inde-
pendent selection and spread before the primary cancer
causes clinical symptoms.
Conclusion
We conclude that CUPs are characterized by chromo-
some instability, which distinguishes them from metasta-
ses of known origin. We propose that CIN and parallel
metastatic behavior may be implicated in early dissemin-
ation and poor outcome of CUPs.
Availability of supporting data
Gene expression CEL files are available at Gene Expres-
sion Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/)
(Testset: GSE2109, GSE7307, GSE6004, GSE6764, GSE10135,
GSE2328, GSE13471, GSE7392 and GSE12606) (Validation-
set: GSE2109, GSE3325, GSE5764, GSE5764, GSE5787,
GSE7307, GSE7476, GSE7553, GSE10245, GSE11151,
GSE14762, GSE15471, GSE17537, GSE19826, GSE19829,
GSE20565) or at ArrayExpress https://www.ebi.ac.uk/
arrayexpress/ accession E-MTAB-3222 (samples collected
and processed at our own facility). Thyroid samples can
be retrieved from accession E-MEXP-2442. The specific
identifiers are depicted in Additional file 1: Table S1.
Supplemental scripts for the outlier analysis and classi-
fier are available at: http://www.genomic-medicine.dk/
recent-papers-and-additional-f/supplemental-files-for-
recent-publications/.
Additional files
Additional file 1: Classification and outlier scores of primary
tumors, metastasis and CUP.
Additional file 2: Figure S1. CUP patients and the processing of tumor
samples. Sixty-eight CUP patients were consecutively enrolled in the
study. In 60 patients the biopsy was obtained during the diagnosticwork-up, whereas eight patients received first-line CUP therapy prior to
the biopsy. Eleven tumor samples were excluded because the RNA integrity
or yield did not meet the required quality criteria. In this way the number of
CUP patients ended up at 57. During the diagnostic work a primary tumor
site was identified in 23 patients (Table 1) and a consensus diagnosis based
on patient demographics, metastatic pattern, results of clinical and laboratory
tests, imaging data and pathological evaluations was obtained in five patients
as described. In 29 patients the primary tumor site remained unknown.
Additional file 3: Table S2. Prediction of tumor classes with the 428
and 641 classifiers.
Additional file 4: Figure S2. Gene families and tumormarkers A. The 10
most selective transcripts in the 641 classifier for each tumor class. Transcripts
were selected by comparison of the indicated tumor class with all other
primary cancers and normal tissues and the ten transcripts exhibiting
the lowest p value are shown. Due to the small sample number in
cholangiocarcinoma and hepatocellular carcinoma, transcripts exhibited
p < 0.01 and 10−4, respectively. For all other groups p < 10−10. Genes marked
in red were considered to be almost exclusive to the class. B. Comparison of
gene families in the patomarker and 641 classifier gene sets. Gene symbols of
the two gene sets were submitted to the Brookhaven gene set enrichment
analysis molecular signatures database (http://www.broadinstitute.org/gsea/
msigdb) and examined with the Gene Families feature. The diagram shows
the percentage of transcripts in each functional category. The 641 classifier
transcripts are shown in red bars and the patomarkers are shown in blue bars.
Additional file 5: Figure S3. Percentage of normal cells in CUP
biopsies and QDA derived outlier scores. The percentage of normal cells
in the CUP biopsies was determined by comparing the levels of liver
(APOA2, ALB), muscle (ACTA1), lymph node (IGJ, IGHA1, IGKV3-20) and skin
(KRT2, TYRP1) specific transcripts in the samples with the expression of
the transcripts in corresponding normal tissues where the biopsies were
obtained. The number indicates the CUP sample code and samples
labeled in yellow were classified as normal tissue. The blue graph shows
the corresponding outlier score generated by the QDA analysis.
Additional file 6: Table S4. Forty most up–-(red) or down–-regulated
(blue) mRNAs in CUP compared to metastasis of known origin. Differentially
expressed transcripts, were retrieved by a class comparison between CUPs
and metastasis The analysis was performed as a paired analysis with respect
to the LDA predictions to eliminate differences related to the individual
tumor classes. Metastases from endometrial, testis, prostate, melanoma and
thyroid cancers were excluded from the analysis because no CUP had been
allocated to these groups by the LDA. CUPs predicted as normal tissue were
also excluded.
Additional file 7: Figure S4. Schematic representation of CUP enriched
BRCA1 DNA damage response and non-homologous end joining repair
networks. Diagrams were generated by the Ingenuity software (Ingenuity
systems, USA). Up-regulated factors are indicated in red.
Additional file 8: Table S3. LDA predictions in CUP.Competing interests
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